Skip to main content

Table 3 Results of the time to event analysis among PWD and PWOD with NHA receiving care for chronic conditions

From: The influence of primary care quality on nursing home admissions in a multimorbid population with and without dementia in Germany: a retrospective cohort study using health insurance claims data

Disease group PWD PWOD
Adjusted HRa Lower
95% CI
Upper
95% CI
Adjusted HRa Lower
95% CI
Upper
95% CI
Hypertension and diabetes
 Medication for hypertension 1.26 0.97 1.63 1.00 0.82 1.21
 Check of HbA1c 0.62* 0.54 0.72 0.54* 0.48 0.61
 Ophthalmological examination 0.60* 0.48 0.75 0.59* 0.50 0.69
 Fundus examination 0.53* 0.38 0.75 0.45* 0.35 0.58
 Acute inpatient treatment of Diabetes 2.67* 1.99 3.60 2.81* 2.28 3.47
 Check of triglycerides and cholesterol 0.70* 0.54 0.90 0.70* 0.58 0.84
 Check of serum-creatinine 0.72* 0.63 0.83 0.69* 0.62 0.77
 Lower-limb amputation 3.10* 1.78 5.55 2.81* 1.94 4.08
Hypertension and depression
 Medication for hypertension 1.00 0.57 1.74 0.81 0.50 1.31
 Antidepressive medication 0.98 0.80 1.21 1.37* 1.15 1.63
Hypertension and COPD
 Medication for hypertension 0.46 0.11 1.94 0.42 0.16 1.14
 Inhaled medication 0.54* 0.35 0.84 0.79 0.61 1.02
 Non-useful inhaled medication --b --b --b --b --b --b
 Acute inpatient treatment of COPD 4.21* 2.20 8.10 2.54* 1.64 3.93
 Respiratory therapy 0.86 0.43 1.72 1.15 0.79 1.68
 Influenza vaccination 0.64 0.33 1.27 0.79 0.50 1.26
 Specific beta-blocker therapy 0.89 0.62 1.29 0.78 0.60 1.01
 Specific anticholinergic therapy 0.62 0.34 1.12 1.17 0.88 1.56
 Oral corticosteroids 1.40 0.82 2.35 0.86 0.58 1.26
Hypertension and diabetes and depression
 Medication for hypertension 0.96 0.54 1.70 0.61 0.32 1.15
 Check of HbA1c 0.62* 0.47 0.82 0.49* 0.38 0.62
 Ophthalmological examination 0.53* 0.34 0.81 0.57* 0.41 0.80
 Fundus examination 0.40* 0.20 0.77 0.56* 0.35 0.89
 Acute inpatient treatment of Diabetes 2.12* 1.20 3.74 2.89* 1.82 4.59
 Check of triglycerides and cholesterol 0.80 0.52 1.23 0.56* 0.36 0.85
 Check of serum-creatinine 0.82 0.63 1.07 0.62* 0.49 0.79
 Lower-limb amputation 2.05 0.47 8.88 2.26 0.68 7.59
 Antidepressive medication 1.28 0.99 1.66 1.30* 1.02 1.64
Hypertension and diabetes and COPD
 Medication for hypertension 1.02 0.35 2.93 0.68 0.29 1.58
 Inhaled medication 0.80 0.43 1.50 0.80 0.57 1.11
 Non-useful inhaled medication --b --b --b --b --b --b
 Acute inpatient treatment of COPD 2.11 0.50 8.85 1.39 0.64 3.00
 Respiratory therapy 1.69 0.87 3.27 1.47 0.93 2.33
 Influenza vaccination 0.83 0.37 1.84 0.92 0.53 1.60
 Specific beta-blocker therapy 0.65 0.49 1.34 0.74 0.54 1.03
 Specific anticholinergic therapy 1.16 0.58 2.31 0.82 0.55 1.21
 Oral corticosteroids 0.47 0.11 1.96 0.99 0.61 1.60
 Check of HbA1c 0.33* 0.19 0.59 0.48* 0.35 0.66
 Ophthalmological examination 0.18* 0.06 0.59 0.64* 0.42 0.99
 Fundus examination 0.12* 0.02 0.91 0.66 0.38 1.17
 Acute inpatient treatment of Diabetes 0.69 0.15 3.17 2.51* 1.26 5.00
 Check of triglycerides and cholesterol 0.37 0.13 1.0 0.87 0.55 1.37
 Check of serum-creatinine 0.56* 0.34 0.91 0.68* 0.50 0.92
 Lower-limb amputation 2.04 0.20 20.97 0.80 0.11 5.82
Hypertension and diabetes and heart failure
 Medication for hypertension 0.83 0.23 3.02 0.63 0.27 1.46
 Beta-blocker upon heart failure 1.24 0.70 2.17 1.03 0.68 1.57
 ACE-inhibitor upon heart failure 0.65 0.36 1.19 1.26 0.82 1.96
 Short acting calcium channel blockers --b --b --b 0.00 0.00 0.00
 Acute inpatient treatment of heart failure 1.08 0.41 2.89 1.55 0.85 2.83
 Check of HbA1c 0.54* 0.30 0.96 0.52* 0.35 0.76
 Ophthalmological examination 0.59 0.17 1.38 0.39* 0.20 0.75
 Fundus examination 0.43 0.10 1.87 0.33* 0.12 0.89
 Acute inpatient treatment of Diabetes 2.65 0.90 7.77 3.19* 1.65 6.16
 Check of triglycerides and cholesterol 0.51 0.20 1.31 0.68 0.36 1.26
 Check of serum-creatinine 0.56 0.32 1.00 0.53* 0.36 0.78
 Lower-limb amputation 1.24 0.19 8.23 2.84 0.91 8.84
  1. NHA Nursing home admission, PWD People with dementia, POWD People without dementia, HR Hazard ratio, CI Confidence interval, COPD Chronic obstructive pulmonary disease, Diabetes Diabetes mellitus type 2
  2. *Significance level alpha < 0.05
  3. aAdjusted for 9 individual-level covariates: age, sex, level of care, direct social network, number of cognitive impairments, number of functional impairments, osteoarthritis, osteoporosis, Charlson comorbidity index
  4. bno results determined due to small number of participants in the numerator of the indicator